immunology-2018-posters-abstracts

Immunology 2018

J u l y 0 5 - 0 7 , 2 0 1 8

V i e n n a , A u s t r i a

Page 102

Journal of Clinical Immunology and Allergy

ISSN 2471-304X

1 5

t h

I n t e r n a t i o n a l C o n f e r e n c e o n

Immunology

ancer immunotherapy is coming of age; it has prompted a paradigm shift in oncology, in which therapeutic agents are used

to target immune cells rather than cancer cells. The first generation of new immunotherapies corresponds to antagonistic

antibodies that block specific immune checkpoint molecules cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), programmed

cell death protein (PD-1) and its ligand PD-L1. Targeting these checkpoints in patients living with cancer had led to long-lasting

tumour responses. By unbalancing the immune system, these new immunotherapies also generate dysimmune toxicities, called

immune-related adverse events (IRAEs) that mainly involve the gut, skin, endocrine glands, liver, and lung but can potentially

affect any tissue. In view of their undisputed clinical efficacy, anti-CTLA-4 and anti-PD-1 antibodies are entering in the routine

oncological practice, and the number of patients exposed to these drugs will increase dramatically in the near future. Although

steroids can be used to treat these IRAEs, the associated immunosuppression may compromise the antitumour response.

Oncologists must be ready to detect and manage these new types of adverse events. This topic will focus on the mechanisms

of IRAE generation, putative relationship between dysimmune toxicity and antitumour efficacy, immune-haematological and

emergent IRAEs, and basis for management guidelines.

Immune-related adverse events with immune

checkpoint blockade therapies

J M Michot

Gustave Roussy Cancer Campus, France

Hopital du Kremlin Bicêtre Assistance Publique des Hôpitaux de Paris, France

Insights Allergy Asthma Bronchitis 2018, Volume: 4

DOI: 10.21767/2471-304X-C1-003